LDE225 (also known as Erismodegib/Sonidegib) is a SMO inhibitor as evidenced in vitro and in vivo as a SMO antagonist (D’Amato et al., 2014), and is currently marketed as Odomzo® to treat advanced stage basal cell carcinoma (BCC) [NCT04066504]. This evidence concerns the gene SMO and skin basal cell carcinoma.